|Mr. Scott Daniel Cormack||Founder, CEO, Pres, Treasurer, Sec. & Director||541.38k||N/A||52|
|Mr. John A. Bencich M.B.A.||VP & CFO||307.5k||N/A||40|
|Dr. Cindy Jacobs Ph.D., M.D.||Exec. VP & Chief Medical Officer||413.23k||N/A||59|
|Ms. Jaime Welch||VP of Marketing & Corp. Communications||N/A||N/A||N/A|
|Dr. Patricia S. Stewart M.D.||VP of Clinical Devel.||N/A||N/A||75|
OncoGenex Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapies that address treatment resistance in cancer patients. It is developing Apatorsen to block the production of heat shock protein 27, a cell-survival protein expressed in various types of cancers, including bladder, prostate, breast, pancreatic, and non-small cell lung cancer. The company is headquartered in Bothell, Washington.
OncoGenex Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.